Holen Sie sich die Stockscreener-App
10.01
2.44%
-0.25
Handel nachbörslich:
10.07
0.06
+0.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$10.26
Offen:
$10.19
24-Stunden-Volumen:
1.50M
Relative Volume:
0.81
Marktkapitalisierung:
$1.30B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-16.15
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
-10.38%
1M Leistung:
-21.74%
6M Leistung:
+58.64%
1J Leistung:
-21.31%
1-Tages-Spanne:
$10.00
$10.38
1-Wochen-Bereich:
$9.28
$11.61
52-Wochen-Spanne:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.01 | 1.33B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
EV Market: Can NeoGenomics Inc deliver alpha2025 Year in Review & Smart Investment Allocation Insights - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Trading Down 8.9%Should You Sell? - MarketBeat
NeoGenomics (NEO) Stock Drops After 2026 Outlook Misses ExpectationsNews and Statistics - IndexBox
Weekly Trades: Will ChoiceOne Financial Services Inc benefit from green energy policies2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Why NeoGenomics (NEO) Shares Are Falling Today - Finviz
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook - Finviz
NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent By Investing.com - Investing.com South Africa
Labcorp (LH) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics PanTracer Pro Launch Adds New Dimension To Growth Story - Yahoo Finance
NeoGenomics Earnings Call Signals Growth With Caveats - TipRanks
Needham raises Neogenomics stock price target on 2027 estimates - Investing.com Australia
Needham raises Neogenomics stock price target on 2027 estimates By Investing.com - Investing.com South Africa
NeoGenomics (NASDAQ:NEO) Shares Gap DownTime to Sell? - MarketBeat
NeoGenomics Q4 2025 Earnings Call Transcript - MarketBeat
NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent - Investing.com
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results - BioSpace
NeoGenomics Q4 Earnings Call Highlights - MarketBeat
NeoGenomics, Inc. (NEO) Investor Outlook: Assessing The 27.97% Potential Upside - DirectorsTalk Interviews
Earnings call transcript: NeoGenomics Q4 2025 earnings beat expectations - Investing.com
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeoGenomics: Q4 Earnings Snapshot - KVUE
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
NeoGenomics Q4 2025 Earnings Report & 2026 Guidance | Financial ResultsNews and Statistics - IndexBox
NeoGenomics shares fall over 5% despite earnings beat By Investing.com - Investing.com South Africa
NeoGenomics shares fall over 5% despite earnings beat - Investing.com UK
Neogenomics reports fourth quarter and full year 2025 results - marketscreener.com
NeoGenomics’s (NASDAQ:NEO) Q4 CY2025 Sales Beat Estimates - Yahoo Finance
NeoGenomics (NASDAQ:NEO) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
NEOGENOMICS ($NEO) Releases Q4 2025 Earnings - Quiver Quantitative
(NEO) NeoGenomics Expects Full Year 2026 Revenue Range $793M$801M, vs. FactSet Est of $796.6M - marketscreener.com
Earnings Flash (NEO) NeoGenomics, Inc. Reports Q4 Revenue $190.2M, vs. FactSet Est of $188.5M - marketscreener.com
Press Release: NeoGenomics Reports Fourth Quarter and Full Year 2025 Results - 富途牛牛
How NeoGenomics (NASDAQ:NEO) Performs Amid Fluctuations In Nasdaq Today - Kalkine Media
NeoGenomics, Inc. (NASDAQ:NEO) Sees Significant Growth in Short Interest - MarketBeat
NeoGenomics: Fourth Quarter Earnings Overview - Bitget
Exploring NeoGenomics's Earnings Expectations - Benzinga
NeoGenomics earnings in the spotlight as analysts eye profitability - Investing.com UK
NeoGenomics earnings in the spotlight as analysts eye profitability By Investing.com - Investing.com Canada
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro - Finviz
NeoGenomics (NEO) Q4 Earnings Report Preview: What To Look For - Finviz
Will PanTracer Pro’s Integrated Tumor Profiling Platform Change NeoGenomics’ (NEO) Precision Oncology Narrative? - Yahoo Finance
NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance - Sahm
How (NEO) Movements Inform Risk Allocation Models - Stock Traders Daily
Can NeoGenomics Inc. stock outperform in a bear marketBear Alert & Short-Term Swing Trade Alerts - mfd.ru
Can NeoGenomics Inc. deliver alphaWeekly Stock Report & Weekly Consistent Profit Watchlists - mfd.ru
Will NeoGenomics Inc. stock benefit from sector rotationJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - mfd.ru
Will NeoGenomics Inc. stock reach Wall Street targetsJuly 2025 Update & Verified Entry Point Signals - mfd.ru
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):